As previously shown for siRNA-mediated knockdown and tucatinib treatment (Figures 4, 5), our experiments support the conclusion that ErbB2 is dispensable for the initial stages of infection such as binding and entry platform formation. This evidence concerns the gene ERBB2 and infection.